1. A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY. (21st February 2022) Authors: Panaccione, R; Danese, S; Zhouwen, W; Pangan, A; Hébuterne, X; Nakase, H; D'Haens, G; Panes, J; Lindsay, J; Higgins, P; Loftus, E; Sandborn, W; Xie, W; Sanchez gonzalez, Y; Liu, J; Weinreich, M; Vermeire, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Issue 14 (1st May 2014) Authors: Higgins, P; Walters, M R; Murray, H M; McArthur, K; McConnachie, A; Lees, K R; Dawson, J Journal: Heart Issue: Volume 100:Issue 14(2014) Page Start: 1085 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme. (21st January 2022) Authors: Higgins, P; Colombel, J F; Reguiero, M; Parkes, G; Ilo, D; Philips, C; Yao, X; Cheng, E; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i088 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FACTORS INVOLVED IN READMISSIONS FOR OLDER VETERANS RECEIVING EARLY HOMECARE. (11th November 2018) Authors: Hornick, T; Fine-Smilovich, E; Banks, R; Knighton, S; Slivka, J; Al Battashi, H; Higgins, P Journal: Innovation in aging Issue: Volume 2(2018)Supplement 1 Page Start: 490 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study. (27th May 2021) Authors: Danese, S; Vermeire, S; Zhou, W; Pangan, A; Siffledeen, J; Hébuterne, X; Nakase, H; Higgins, P; Chen, M H; Sanchez-Gonzalez, Y; Huang, B; Xie, W; Liu, J; Weinreich, M; Pannaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S022 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P224 Responder definitions for the ulcerative colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) tool using patients with ulcerative colitis treated with etrolizumab. (25th January 2019) Authors: Higgins, P; Matsui, A; DeBusk, K; Pulley, J; Scalori, A; Oh, Y S; Arulmani, U Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P253 Could application of simple diagnostic algorithm aid onward referral for optimisation of pre-existing conditions in patients being considered for major surgery?. (15th November 2016) Authors: Hornsby, J; Higgins, P; Baker, A; Black, E; Anderson, D Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance. (21st January 2022) Authors: Panés, J; Loftus, E V J; Higgins, P; Lindsay, J O; Zhou, W; Yao, X; Ilo, D; Phillips, C; Tran, J; Sanchez Gonzalez, Y; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn's disease. (25th January 2019) Authors: Higgins, P; Ginsburg, D; Gilder, K; Gilder, K; Walsh, B; English, B; Turner, S; Klassen, P; Hanauer, S; Barish, C; Yacyshyn, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. (21st January 2022) Authors: Colombel, J F; Panaccione, R; Nakase, H; Burmester, G; Cohen, S B; Mease, P; Guttman-Yassky, E; Liu, J; Zhou, W; Ilo, D; Higgins, P Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗